#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	18618	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2597	881.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1626	1626	C	1227	C,T	1225,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31756	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4106	962.7	0	.	n	.	0	T695C	SNP	695	695	T	1227	1227	C	1155	C,T,A	1150,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31756	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4106	962.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1869	1869	A	1278	A,C,T,G	1275,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31756	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4106	962.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2503	2503	C	1135	C,T,G,A	1131,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31756	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4106	962.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2577	2577	A	1058	A,G,C	1052,2,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31756	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4106	962.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3129	3129	C	1121	C,A,T	1118,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2884	folP	855	855	100.0	folP.l6.c4.ctg.1	2074	173.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1318	1320	AGC	287;288;291	A;G,T;C	287;287,1;291	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6524	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3747	216.7	1	SNP	p	S91F	1	.	.	271	273	TTC	743	745	TTC	227;226;225	T;T;C,T	227;226;224,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6524	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3747	216.7	1	SNP	p	D95G	1	.	.	283	285	GGC	755	757	GGC	228;230;228	G,A;G,C;C	227,1;229,1;228	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6524	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3747	216.7	1	SNP	p	G95N	0	.	.	283	285	GGC	755	757	GGC	228;230;228	G,A;G,C;C	227,1;229,1;228	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2556	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1760	180.7	1	SNP	p	G45D	0	.	.	133	135	GGC	671	673	GGC	295;293;293	G;G;C,G	294;292;292,1	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1396	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1485	117.0	0	.	n	.	0	A197.	DEL	197	197	A	845	845	A	269	A	269	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6540	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3567	228.4	1	SNP	p	D86N	0	.	.	256	258	GAC	956	958	GAC	308;308;305	G,A;A;C,G	307,1;308;304,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6540	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3567	228.4	1	SNP	p	R87I	0	.	.	259	261	CGT	959	961	CGT	307;308;305	C;G,A;T,C	307;307,1;303,2	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6540	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3567	228.4	1	SNP	p	S87R	1	.	.	259	261	CGT	959	961	CGT	307;308;305	C;G,A;T,C	307;307,1;303,2	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6540	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3567	228.4	1	SNP	p	R87W	0	.	.	259	261	CGT	959	961	CGT	307;308;305	C;G,A;T,C	307;307,1;303,2	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6540	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3567	228.4	1	SNP	p	S88P	0	.	.	262	264	TCC	962	964	TCC	306;303;304	T,G;C;C	305,1;303;304	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5406	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3172	212.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1853	1855	GGC	294;295;292	G;G;C	294;294;292	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1491	1493	GCA	301;303;302	G,C;C,A;A,C	300,1;302,1;301,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1494	1496	ATC	301;300;300	A;T;C	301;300;299	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1506	1508	GTG	300;301;301	G;T;G	299;300;301	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1506	1508	GTG	300;301;301	G;T;G	299;300;301	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2010	2012	ACC	309;309;312	A;C,T;C,T	309;308,1;311,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2064	2066	GCG	299;299;298	G;C,A,G;G	299;297,1,1;298	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2064	2066	GCG	299;299;298	G;C,A,G;G	299;297,1,1;298	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2187	2189	AGC	267;261;261	A,G;G;C,A	266,1;261;260,1	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2196	2198	GGC	259;261;263	G;G,T;C	259;260,1;263	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5116	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2856	223.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2214	2216	CCG	274;280;281	C;C,G;G	274;279,1;281	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7350	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3606	254.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1932	1934	CCG	284;282;283	C,G,T;C;G,T	282,1,1;282;281,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3308	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2397	172.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	904	904	C	277	C	277	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	28;29;32	T;T;A	28;29;32	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	72;72;72	C;A;T	72;72;72	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	72;72;72	A;G;T	72;72;72	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	72;72;72	T;A;C	72;72;72	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	4;4;4	T;C;G	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	553	25.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	5;5;6	G;T;T	5;5;6	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	356	porB1a	984	93	95.7	porB1a.l15.c17.ctg.4	168	65.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	124	126	ACG	75;73;70	A;C;G	75;73;70	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	603	605	GAA	318;316;313	G,C;A,T,G;A,C	317,1;314,1,1;312,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	0	.	p	.	0	V47M	NONSYN	139	141	GTG	630	632	ATG	309;308;312	A,C;T;G	307,1;307;312	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1014	1016	TCA	354;352;353	T,G,C;C,A;A	352,1,1;351,1;353	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1473	1475	GCA	279;280;278	G,T;C,A;A	278,1;277,1;276	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	1	SNP	p	G120K	1	.	.	358	360	AAG	849	851	AAG	302;306;305	A;A,G;G,C,A	302;304,1;303,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	1	SNP	p	D121N	0	.	.	361	363	GAC	852	854	GAC	305;306;307	G,A;A,C;C,A	304,1;305,1;306,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3732	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1902	242.9	1	SNP	p	A121D	1	.	.	361	363	GAC	852	854	GAC	305;306;307	G,A;A,C;C,A	304,1;305,1;306,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12324	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5338	287.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1738	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1564	138.6	1	SNP	p	V57M	1	.	.	169	171	ATG	754	756	ATG	318;316;315	A,G;T;G,A	317,1;316;314,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
